Stephen Basil Thomas

CIK: 0002027962

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)3 (27.3%)

Derivative conversions

Awards (A)3 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CLYM

Climb Bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

CLYM
Climb Bio, Inc.
Sep 15, 2026
Sale(S)
Direct
100K shares at avg. $13.67$1.4M
CLYM
Climb Bio, Inc.
Jun 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
CLYM
Climb Bio, Inc.
Feb 26, 2026
Sale(S)
Direct
16.3K shares at avg. $7.01$114K
CLYM
Climb Bio, Inc.
Feb 25, 2026
Sale(S)
Direct
33.7K shares at avg. $7.00$236K
CLYM
Climb Bio, Inc.
Feb 13, 2026
Sale(S)
Direct
10K shares at avg. $5.81$58K
CLYM
Climb Bio, Inc.
Feb 12, 2026
Sale(S)
Direct
90K shares at avg. $5.23$471K
CLYM
Climb Bio, Inc.
Aug 7, 2025
Award(A)
Direct
100.4K shares-
CLYM
Climb Bio, Inc.
Jun 27, 2025
Exercise(M)
Direct
25.1K shares-
CLYM
Climb Bio, Inc.
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
40K shares-
CLYM
Climb Bio, Inc.
Mar 27, 2025
Exercise(M)
Direct
25.1K shares-
CLYM
Climb Bio, Inc.
Jan 1, 2025
Exercise(M)
Direct
50.2K shares-

		Type	Shares	Price		Ownership
Sep 15, 2026	CLYM Climb Bio, Inc.	Sale(S)	100,000	$13.67	$1,366,820	Direct
Jun 5, 2026	CLYM Climb Bio, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Feb 26, 2026	CLYM Climb Bio, Inc.	Sale(S)	16,313	$7.01	$114,289	Direct
Feb 25, 2026	CLYM Climb Bio, Inc.	Sale(S)	33,687	$7.00	$235,964	Direct
Feb 13, 2026	CLYM Climb Bio, Inc.	Sale(S)	10,000	$5.81	$58,141	Direct
Feb 12, 2026	CLYM Climb Bio, Inc.	Sale(S)	90,000	$5.23	$470,988	Direct
Aug 7, 2025	CLYM Climb Bio, Inc.	Award(A)	100,375	-	-	Direct
Jun 27, 2025	CLYM Climb Bio, Inc.	Exercise(M)	25,094	-	-	Direct
Jun 4, 2025	CLYM Climb Bio, Inc.	Award(A) Stock Option (Right to Buy)	40,000	-	-	Direct
Mar 27, 2025	CLYM Climb Bio, Inc.	Exercise(M)	25,093	-	-	Direct
Jan 1, 2025	CLYM Climb Bio, Inc.	Exercise(M)	50,188	-	$0	Direct

1-11 of 11 transactions

About Thomas Stephen Basil

Thomas Stephen Basil (SEC CIK 0002027962) files insider reports with the SEC as Director of Climb Bio, Inc. (CLYM).

Signal8 holds 9 ownership filings by Thomas Stephen Basil, all Form 4s, filed between Jan 3, 2025 and Sep 17, 2026. Those filings report 11 transactions, from Jan 1, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Thomas Stephen Basil's filings is in WELLESLEY HILLS, MA.

Recent filings by Thomas Stephen Basil

Sep 15, 2026: Open-market sale of CLYM shares (Form 4, code S).
Jun 5, 2026: Grant or award of CLYM derivative securities (Form 4, code A).
Feb 26, 2026: Open-market sale of CLYM shares (Form 4, code S).
Feb 25, 2026: Open-market sale of CLYM shares (Form 4, code S).
Feb 13, 2026: Open-market sale of CLYM shares (Form 4, code S).

Other insiders filing for Climb Bio, Inc. (CLYM)

How to read Form 4 transaction codes